Abstract 1434P
Background
FRUTIGA study showed OS improvement but was not statistically significant in the ITT population who had advanced G/GEJ adenocarcinoma receiving F plus PTX over placebo plus PTX (mOS: 9.67 vs 8.41 mo, HR=0.96, p=0.6064; Xu RH, et al, 2024 ASCO #438780). Here we explored the effect of subsequent anti-tumor therapies on OS in this study.
Methods
A post-hoc analysis for the effect of subsequent anti-tumor therapies on OS (randomization to death from any cause) using Kaplan-Meier method was conducted.
Results
A total of 439/703 pts (F+PTX vs placebo + PTX: 185/351 [52.7%] vs 254/352 [72.2%]) received subsequent anti-tumor therapies. There were 33.7% (28.2% vs 39.2%), 16.9% (14.2% vs 19.6%), and 9.1% (7.4% vs 10.8%) of pts received 1, 2 or ≥ 3 subsequent anti-tumor regimens, respectively. Apatinib (23.1% vs 35.2%), irinotecan (20.8% vs 27.8%) and anti PD-1/PD-L1 antibodies (20.8% vs 27.6%) were the most common subsequent regimens; few pts (3.4% vs 5.7%) used anti-HER2/Claudin 18.2 regimens. Detailed results of impact of subsequent anti-tumor therapies on OS are shown in the table below. Table: 1434P
| F+PTX (N = 351) n (%) | PTX (N = 352) n (%) | Median OS, mo (F+PTX vs PTX) | HR | |
| Subsequent treatment | 185 (52.7) | 254 (72.2) | 12.22 vs 9.95 | 0.91 (0.73, 1.12) |
| Apatinib | 81 (23.1) | 124 (35.2) | 13.01 vs 10.81 | 0.95 (0.70, 1.30) |
| Irinotecan | 73 (20.8) | 98 (27.8) | 12.22 vs 10.71 | 0.92 (0.67, 1.27) |
| Anti PD-1/PD-L1 – ICI naïve# | 68 (19.4) | 86 (24.4) | 13.90 vs 13.60 | 1.12 (0.77, 1.62) |
| Anti PD-1/PD-L1 – ICI pre-treated∗ | 5 (1.4) | 11 (3.1) | 14.52 vs 14.75 | 0.73 (0.18, 2.94) |
| Anti HER2/Claudin 18.2& | 12 (3.4) | 20 (5.7) | 13.77 vs 16.10 | 2.09 (0.82, 5.30) |
∗Pts who had received prior anti PD-1/PD-L1 antibodies treatment.#Pts who had not received prior anti PD-1/PD-L1 antibodies treatment.&Pts who had not received prior HER2.
Conclusions
Pts who received 3L standard regimens (apatinib, irinotecan) for the subsequent anti-tumor therapies had the consistent OS improvement as shown in ITT population. Subsequent anti PD-1/PD-L1 therapies for pts who had received previous anti PD-1/PD-L1 antibodies could have no potential impact on OS benefit in FRUTIGA study.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
P. Tan, W. Su: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16